In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Harvard Bioscience Inc’s stock clocked out at $1.98, up 4.21% from its previous closing price of $1.90. In other words, the price has increased by $4.21 from its previous closing price. On the day, 1.35 million shares were traded. HBIO stock price reached its highest trading level at $1.98 during the session, while it also had its lowest trading level at $1.81.
Ratios:
To gain a deeper understanding of HBIO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 102.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.91 and its Current Ratio is at 2.06. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, The Benchmark Company on March 10, 2023, Upgraded its rating to Buy and sets its target price to $4 from $3 previously.
On December 09, 2020, Northland Capital started tracking the stock assigning a Outperform rating and target price of $6.Northland Capital initiated its Outperform rating on December 09, 2020, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’24 when Green James W bought 10,000 shares for $2.91 per share. The transaction valued at 29,100 led to the insider holds 3,111,091 shares of the business.
Green James W bought 20,000 shares of HBIO for $61,400 on Jun 06 ’24. The Chief Executive Officer now owns 3,101,091 shares after completing the transaction at $3.07 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 86360872 and an Enterprise Value of 127705912. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.88 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 1.307 whereas that against EBITDA is 44.312.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.28, which has changed by -0.58515286 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $4.93, while it has fallen to a 52-week low of $1.88. The 50-Day Moving Average of the stock is -10.54%, while the 200-Day Moving Average is calculated to be -31.66%.
Shares Statistics:
It appears that HBIO traded 167.78K shares on average per day over the past three months and 205710 shares per day over the past ten days. A total of 43.62M shares are outstanding, with a floating share count of 40.16M. Insiders hold about 7.92% of the company’s shares, while institutions hold 71.96% stake in the company. Shares short for HBIO as of 1734048000 were 533073 with a Short Ratio of 3.90, compared to 1731628800 on 374062. Therefore, it implies a Short% of Shares Outstanding of 533073 and a Short% of Float of 1.3099999.
